Natixis Advisors’s ResMed RMD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $4.47M | Sell |
22,926
-42,320
| -65% | -$8.77M | 0.01% | 946 |
|
|
2026
Q1 | $14.6M | Buy |
65,246
+15,837
| +32% | +$3.95M | 0.02% | 576 |
|
|
2025
Q4 | $11.9M | Buy |
49,409
+987
| +2% | +$252K | 0.02% | 618 |
|
|
2025
Q3 | $13.3M | Sell |
48,422
-237
| -0.5% | -$64.7K | 0.02% | 596 |
|
|
2025
Q2 | $12.6M | Sell |
48,659
-12,952
| -21% | -$3.09M | 0.02% | 605 |
|
|
2025
Q1 | $13.8M | Buy |
61,611
+4,500
| +8% | +$1.05M | 0.03% | 558 |
|
|
2024
Q4 | $13.1M | Buy |
57,111
+5,613
| +11% | +$1.35M | 0.02% | 575 |
|
|
2024
Q3 | $12.6M | Buy |
51,498
+12,445
| +32% | +$2.78M | 0.02% | 588 |
|
|
2024
Q2 | $7.48M | Buy |
39,053
+372
| +1% | +$75.5K | 0.02% | 696 |
|
|
2024
Q1 | $7.66M | Buy |
38,681
+3,234
| +9% | +$593K | 0.02% | 683 |
|
|
2023
Q4 | $6.1M | Buy |
35,447
+3,923
| +12% | +$603K | 0.02% | 697 |
|
|
2023
Q3 | $4.66M | Sell |
31,524
-64,082
| -67% | -$11.6M | 0.01% | 730 |
|
|
2023
Q2 | $20.9M | Sell |
95,606
-123
| -0.1% | -$27.4K | 0.06% | 313 |
|
|
2023
Q1 | $21M | Sell |
95,729
-20,798
| -18% | -$4.51M | 0.07% | 288 |
|
|
2022
Q4 | $24.3M | Sell |
116,527
-42,186
| -27% | -$9.27M | 0.09% | 251 |
|
|
2022
Q3 | $34.6M | Buy |
158,713
+25,542
| +19% | +$5.81M | 0.15% | 167 |
|
|
2022
Q2 | $27.9M | Buy |
133,171
+2,089
| +2% | +$445K | 0.12% | 192 |
|
|
2022
Q1 | $31.8M | Buy |
131,082
+4,084
| +3% | +$988K | 0.12% | 185 |
|
|
2021
Q4 | $33.1M | Buy |
126,998
+1,087
| +0.9% | +$282K | 0.13% | 181 |
|
|
2021
Q3 | $33.2M | Buy |
125,911
+2,776
| +2% | +$759K | 0.14% | 166 |
|
|
2021
Q2 | $30.4M | Buy |
123,135
+5,937
| +5% | +$1.25M | 0.14% | 171 |
|
|
2021
Q1 | $22.7M | Buy |
117,198
+3,970
| +4% | +$796K | 0.12% | 204 |
|
|
2020
Q4 | $24.1M | Sell |
113,228
-7,081
| -6% | -$1.41M | 0.14% | 179 |
|
|
2020
Q3 | $20.6M | Sell |
120,309
-3,498
| -3% | -$646K | 0.13% | 186 |
|
|
2020
Q2 | $23.8M | Sell |
123,807
-1,479
| -1% | -$242K | 0.16% | 158 |
|
|
2020
Q1 | $18.5M | Buy |
125,286
+14,804
| +13% | +$2.36M | 0.15% | 153 |
|
|
2019
Q4 | $17.1M | Buy |
110,482
+16,286
| +17% | +$2.35M | 0.12% | 200 |
|
|
2019
Q3 | $12.7M | Buy |
94,196
+14,756
| +19% | +$1.93M | 0.1% | 232 |
|
|
2019
Q2 | $9.69M | Buy |
79,440
+6,168
| +8% | +$683K | 0.08% | 274 |
|
|
2019
Q1 | $7.62M | Buy |
73,272
+24,043
| +49% | +$2.48M | 0.07% | 335 |
|
|
2018
Q4 | $5.61M | Buy |
49,229
+27,888
| +131% | +$2.99M | 0.06% | 372 |
|
|
2018
Q3 | $2.46M | Sell |
21,341
-26
| -0.1% | -$2.85K | 0.02% | 711 |
|
|
2018
Q2 | $2.21M | Sell |
21,367
-1,187
| -5% | -$120K | 0.02% | 742 |
|
|
2018
Q1 | $2.22M | Buy |
22,554
+3,376
| +18% | +$319K | 0.02% | 727 |
|
|
2017
Q4 | $1.62M | Buy |
19,178
+4,579
| +31% | +$378K | 0.02% | 763 |
|
|
2017
Q3 | $1.12M | Sell |
14,599
-908
| -6% | -$69.5K | 0.01% | 851 |
|
|
2017
Q2 | $1.21M | Buy |
15,507
+504
| +3% | +$36.1K | 0.01% | 823 |
|
|
2017
Q1 | $1.08M | Sell |
15,003
-757
| -5% | -$52.3K | 0.01% | 846 |
|
|
2016
Q4 | $978K | Buy |
15,760
+706
| +5% | +$43.2K | 0.01% | 835 |
|
|
2016
Q3 | $975K | Sell |
15,054
-2,267
| -13% | -$151K | 0.01% | 811 |
|
|
2016
Q2 | $1.09M | Sell |
17,321
-1,350
| -7% | -$79.6K | 0.02% | 776 |
|
|
2016
Q1 | $1.08M | Buy |
+18,671
| New | +$1.06M | 0.02% | 783 |
|
|
2015
Q2 | – | Sell |
-12,475
| Closed | -$895K | – | 1026 |
|
|
2015
Q1 | $895K | Sell |
12,475
-4,133
| -25% | -$268K | 0.02% | 805 |
|
|
2014
Q4 | $931K | Buy |
16,608
+14
| +0.1% | +$731 | 0.02% | 807 |
|
|
2014
Q3 | $818K | Buy |
16,594
+7,910
| +91% | +$403K | 0.02% | 827 |
|
|
2014
Q2 | $440K | Sell |
8,684
-363
| -4% | -$18K | 0.01% | 1030 |
|
|
2014
Q1 | $404K | Buy |
9,047
+2,130
| +31% | +$95.7K | 0.01% | 992 |
|
|
2013
Q4 | $326K | Buy |
+6,917
| New | +$350K | 0.01% | 1002 |
|
Other funds holding RMD
Natixis Advisors's RMD Position: Q2 2026 in Review
Natixis Advisors reduced its ResMed (RMD) stake by 65% in Q2 2026, selling an estimated $8.77M and leaving 22,926 shares worth $4.47M. The position accounts for 0.01% of the portfolio, ranked #946.
Natixis Advisors first reported a position in RMD in Q4 2013 and has held it in 48 quarters since. The position peaked at $34.6M in Q3 2022. 880 funds tracked by Wall St. Rank hold RMD as of Q2 2026.
- Natixis Advisors held 22,926 shares of ResMed worth $4.47M as of Q2 2026.
- Natixis Advisors sold 42,320 ResMed shares in Q2 2026, an estimated $8.77M.
- ResMed made up 0.01% of Natixis Advisors's portfolio in Q2 2026, its #946 holding.
- Natixis Advisors first reported a position in ResMed in Q4 2013 and has held it in 48 quarters since.
- Natixis Advisors's ResMed position peaked at $34.6M in Q3 2022.
- 880 funds tracked by Wall St. Rank held ResMed as of Q2 2026.
Based on Natixis Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.